All News
ACR21 Best Abstracts - Day 2
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).
Read Article
"Baseline and routine EKGS are NOT required for SLE patients just because they are on HCQ!" - Dr. HM Belmont. "The drug has been demonized due to its use in COVID patients. We don't need to hold HCQ for EMR alerts (e.g, with cipro, SSRIs, etc)." Abstr#1743 #ACR21 @rheumnow https://t.co/5Bxavo6dRg
TheDaoIndex KDAO2011 ( View Tweet)
Anti-NETs antibodies in #COVID.
1️⃣ correlate➖ w/ SpO2/FiO2 ratio (IgG r=-0.17 IgM r=-0.30
2️⃣correlate➕ w/ ⬆️D-dimer (IgG r=0.33 IgM r=0.19
3️⃣ ⬆️ in pts requiring MV
In a study of 328 pts. Probably driving complement activation!
#ACR21 #Abst1430 @RheumNow https://t.co/2MCrLueTzN
Aurelie Najm AurelieRheumo ( View Tweet)
Abst 1550 #acr21 @RheumNow @bryan_neel rheum pts after covid 19 vaccine: 18.9% reported SEs after the 1st dose,33.1% after 2nd dose. most frequent SEs fever, HA, fatigue & arthromyalgia. All mild&self resolved. Disease flare in 1/180 pts (0.6%) 1st dose 4/118 (3.4%) 2nd dose https://t.co/5AB5CJfYt8
Olga Petryna DrPetryna ( View Tweet)
FDA Update: 3 trials showing Efficacy of Tocilizumab in COVID 19:
1. RECOVERY - lower mortality
2. EMPACTA - Less progression to mech vent or death
3. REMDACTA & COVACTA - did not meet primary endpoints (but not contradictory) FDA Metanalysis of all 4 trials #ACR21 EUA 6/21 https://t.co/9yHu87KGej
Dr. John Cush RheumNow ( View Tweet)
FDA Update session: Proven Benefit of Baricitinib in Hospitalized COVID-19 from the ACT2 and COV-BARRIER Studies, showing it does not need to be given with Remdesivir (4 mg qd maz 14days) #ACR21 https://t.co/r6crPtu3ZH
Dr. John Cush RheumNow ( View Tweet)
FDA Update at #ACR21, Dr. Golding reviews the criteria for EUA - Emergency use authorization for new drugs (critically important during COVID-19) Session 8M115 https://t.co/DqmxEIdvWZ D https://t.co/6aQG8yP7RW
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR21 #Abstr1420 A study checking #COVID vaccine response in 90 #lupus pts and 20 HC:
⬇️Titres of Abs in SLE vs controls
💠Factors of poor response: On any DMARDs exc HCQ only (OR 15) and normal dsDNA
📢Important to pause DMARDs in stable SLE @RheumNow https://t.co/USovFkiCRb https://t.co/bn5CC0xRS9
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
📢#ACR21 #Abstr1421 Is #COVID19 vaccine safe and effective in #lupus? YES!! VOCOLUP study (N=1189 pts) showed:
💠~45% had a side-effect; of which 80% mild/moderate
💠Only 3% flared post💉(MSK + Fatigue); 10 required hospitalisation @RheumNow #ACRBest https://t.co/WF4aAfiX70 https://t.co/jc0HQoJymo
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR21 #Abstr1083 Do pts with Autoinflammatory disease flare differently during #COVID19? Survey of N=647 (mostly CAPS):
💠56% No change
💠Of pts who flared, 50% had low/absent fever
💠7% had COVID; mostly mild
Shielding could influence results @RheumNow https://t.co/g7VazLfiT9 https://t.co/lzaSoMEzyR
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Dr FCardwell et al on Health Info use in SLE pts b4 and during COVID19 using an online survey
🦋#lupus specialists & fam physicians - ⬆preferred & trusted health info sources but access to them ⬇frequent during covid19
A call to action?📢
@RheumNow #ACR21 abs0880 @rheumarhyme https://t.co/1NBEAlFvHx
sheila RHEUMarampa ( View Tweet)
Awesome interview w/ @rheum_cat @JYazdanyMD @jeffsparks
video link https://t.co/dVLayNchHT
TheDaoIndex KDAO2011 ( View Tweet)
Please don’t miss MISC (pronounced Miss C)=multisystem inflammatory syndrome. Pediatric syndrome post #SARSCoV2 infection. May go w macrophage activation syndrome (MAS) w distinct proteomics signature. Potentially v poor outcomes. Need to dx and treat #ACR21 abst0961 @RheumNow https://t.co/uaBbUdg3lt
Janet Pope Janetbirdope ( View Tweet)
Dr. Petri on COVID19 infection vs vaccination on SLE activity:
💠Infection = NO increase SLE activity
💠Infection =⬇️ cutaneous activity
💠Infection = ⬆️anti-cardiolipin IgG/M
💠Vaccination: no increase in activity NOR aCL IgG/M
https://t.co/fWbotSLS3o
#ACR21 Abst#0858 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Abstr 0983 mRNA SARS-CoV-2 Vaccine in RA Patients
Rubbert-Roth and colleagues found:
- RA patients developed anti-S1 antibodies slower and lower compared to controls
- Reduced titers among Abatacept & JAKi users
#ACR21 @RheumNow https://t.co/sXW8d53O8m
Akhil Sood MD AkhilSoodMD ( View Tweet)
#ACR21 #Abstr0866 Data from #COVID19 GRA Registry showed predictors of poor COVID outcome in 1922 #lupus pts:
Older age
Male
Areas outside Europe, 🇺🇸🇨🇦
Infection <June 2020
Any Corticosteroid dose
Not on therapy
On Rituximab
Comorbidities
⬆️disease activity
@RheumNow #ACRBest https://t.co/u0GF3aDsFA
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR21 #Abstr0858 Petri reported effect of #COVID and vaccination in #lupus cohort
💠No increase in activity post-infection
💠⬇️cutaneous activity
💠⬆️ aCL IgG and IgM post-infection,
💠No increase in SLE activity or aCL abs post-vaccination
@RheumNow https://t.co/iAaIfzf33c https://t.co/hA6sk6icrs
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Andy 0963 #ACR21 @RheumNow covid19 vaccine immunogenicity in rheum pts overall good at 71%, fairly dependent on Rx choice: rituximab 38% after 1g & only 7 % after 1gx2; abatacept IV 45%. Rest biologics >80%, ⬇️MTX &MMF. Low dose prednisone w/out biologics did not affect Ab+ rates https://t.co/TkCC1sgMHG
Olga Petryna DrPetryna ( View Tweet)
Infx oral session
0964 Bitoun, et al.
RTX lowers neutralizing Ab response compared to healthy controls, after COVID vaccination -- more supportive data
https://t.co/6jvWHSjIgr
#ACR21
Rheum Cat rheum_cat ( View Tweet)
Outcomes of COVID-19 in Patients with Rheumatoid Arthritis.
Dr. Akhil Sood ( @AkhilSoodMD) shares the studies presented #ACR21.
https://t.co/yrs8N8XSiS https://t.co/EKHuTS5aDr
Links:
Dr. John Cush RheumNow ( View Tweet)
